<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03029455</url>
  </required_header>
  <id_info>
    <org_study_id>VX16-659-001</org_study_id>
    <secondary_id>2016-003048-35</secondary_id>
    <nct_id>NCT03029455</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis</brief_title>
  <official_title>A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation, and Bioavailability Study Evaluating the Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and tolerability of VX-659 in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability assessments as determined by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>from baseline up to Day 50</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of VX-659 and selected metabolites (μg/mL)</measure>
    <time_frame>from baseline up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of TEZ and selected metabolites (μg/mL)</measure>
    <time_frame>from baseline up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of IVA and selected metabolites (μg/mL)</measure>
    <time_frame>from baseline up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve during a dosing interval (AUCtau) of VX-659 and selected metabolites (μg,h/mL)</measure>
    <time_frame>from baseline up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau of TEZ and selected metabolites (μg,h/mL)</measure>
    <time_frame>from baseline up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau of IVA and selected metabolites (μg,h/mL)</measure>
    <time_frame>from baseline up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed pre-dose concentration (Ctrough) of VX-659 and selected metabolites (μg/mL)</measure>
    <time_frame>from baseline up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of TEZ and selected metabolites (μg/mL)</measure>
    <time_frame>from baseline up to Day 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of IVA and selected metabolites (μg/mL)</measure>
    <time_frame>from baseline up to Day 18</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part A: VX-659 or Matching Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A includes single-dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: VX-659 or Matching Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B includes multiple-dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part C includes multiple dose escalation of VX-659 administered in Triple Combination (TC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part D includes subjects with CF. Participants will receive TC or matching placebos.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-659</intervention_name>
    <arm_group_label>Part A: VX-659 or Matching Placebo</arm_group_label>
    <arm_group_label>Part B: VX-659 or Matching Placebo</arm_group_label>
    <arm_group_label>Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo</arm_group_label>
    <arm_group_label>Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tezacaftor</intervention_name>
    <arm_group_label>Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo</arm_group_label>
    <arm_group_label>Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo</arm_group_label>
    <other_name>VX-661</other_name>
    <other_name>TEZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor</intervention_name>
    <arm_group_label>Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo</arm_group_label>
    <arm_group_label>Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo</arm_group_label>
    <other_name>VX-770</other_name>
    <other_name>IVA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-659 Matching Placebo</intervention_name>
    <arm_group_label>Part A: VX-659 or Matching Placebo</arm_group_label>
    <arm_group_label>Part B: VX-659 or Matching Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple Combination (TC) Matching Placebos</intervention_name>
    <arm_group_label>Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo</arm_group_label>
    <arm_group_label>Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Volunteers: PARTS A, B, and C

          -  Males and Females of non-childbearing potential.

          -  Between the ages of 18 and 60 years inclusive

          -  Healthy, as defined per protocol.

          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive

          -  Body weight &gt;50 kg

        CF Patients: PART D

          -  Body weight ≥35 kg.

          -  Males and Females of non-childbearing potential.

          -  Sweat chloride value ≥ 60 mmol/L at screening.

          -  Heterozygous for F508del and a minimal function CFTR mutation

          -  Forced expiratory volume in 1 second (FEV1) ≥40% and ≤90% of predicted at screening

        Exclusion Criteria:

        Healthy Volunteers: PARTS A, B, and C

          -  History of any illness or any clinical condition that in the opinion of the
             investigator might confound the results of the study or pose additional risk to the
             subject.

          -  Any condition possibly affecting drug absorption.

          -  History of febrile illness within 14 days before the first study drug dose.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening.

        CF Patients: PART D

          -  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk to the subject.

          -  History of cirrhosis with portal hypertension.

          -  Risk factors for Torsade de Pointes.

          -  G6PD deficiency assessed at Screening.

          -  Abnormal Laboratory Values.

          -  Lung infection with organisms associated with a more rapid decline in pulmonary status

          -  History of solid organ or hematological transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2017</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

